Effect of tamoxifen on Ki-67 expression in breast tumor tissue of nude mice transfected with progesterone receptor membrane component 1

doi:10.3969/j.issn.1006-7795.2019.04.008

Abstract

Abstract: Objective To investigate the effect of tamoxifen (TAM) on the expression of proliferative index Ki-67 in breast cancer tissue of MCF-7 breast cancer model transfected with progesterone receptor membrane component 1 (PGRMC1) and its mechanism. Methods MCF-7 cells of breast cancer were cultured, incubated and subcultured, transfected with PGRMC1 (MCF-7-HA-PGRMC1) or empty plasmid (MCF-7-HA-vector), and then they were inoculated into randomly grouped castrated nude mice, including experimental group and control group. Estradiol (E2) sustained release tablets were embedded in 48 castrated nude mice for 48h,then the above two kinds of cells were inoculated into nude mice as experimental group and control group respectively. Additionaly placebo, progesterone, tamoxifen, tamoxifen and progesterone were administrated to each group. After 56 days of implantation, euthanasia was performed. Breast tumor tissues were removed completely under aseptic operation and Ki-67 expression was detected with immunohistochemistry. Results Ki-67 expression in tumor tissues of the experimental group significantly increased compared with that of the control group (P<0.001). In the experimental group, compared E2, E2+TAM combined therapy could reduce the expression of Ki-67 in tumor tissues, with statistically significant difference (P<0.001). However, E2 + progesterone did not promote the expression of Ki-67 (P>0.05). The expression of Ki-67 in E2+progesterone+TAM group significantly lower than that in estradiol +alone (P<0.001). Conclusion PGRMC1 increased the expression of Ki-67 and accelerate cell proliferation. Tamoxifen therapy antagonized pgrmc1-induced proliferation of breast tumor cells by reducing the expression of Ki-67.

Key words: tamoxifen, progesterone receptor membrane component 1 (PGRMC1), breast cancer model, Ki-67

CLC Number:

R711

Zhang Lingyan, Ruan Xiangyan, Cai Guiju, Gu Muqing, Alfred O. Mueck. Effect of tamoxifen on Ki-67 expression in breast tumor tissue of nude mice transfected with progesterone receptor membrane component 1[J]. Journal of Capital Medical University, 2019, 40(4): 533-538.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2019.04.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2019/V40/I4/533

References 23

[1]	Akram M, Iqbal M, Daniyal M, et al. Awareness and current knowledge of breast cancer[J]. Biol Res, 2017, 50(1):33.
[2]	Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013, 20(5):504-510.
[3]	陈万青,郑荣寿. 中国女性乳腺癌发病死亡和生存状况[J]. 中国肿瘤临床,2015,42(13):668-674.
[4]	Harrison G S, Wierman M E, Nett T M, et al. Gonadotropin-releasing hormone and its receptor in normal and malignant cells[J]. Endocr Relat Cancer, 2004, 11(4):725-748.
[5]	Shagufta, Ahmad I. Tamoxifen a pioneering drug:an update on the therapeutic potential of tamoxifen derivatives[J]. Eur J Med Chem, 2018, 143:515-531.
[6]	Peddi P F.Hormone receptor positive breast cancer:state of the art[J].Curr Opin Obstet Gynecol,2018,30(1):51-54.
[7]	Dean L.Tamoxifen Therapy and CYP2D6 Genotype[M]//Pratt V, McLeod H, Rubinstein W, et al. Medical Genetics Summaries. Bethesda (MD):National Center for Biotechnology Information (US),2012.
[8]	丁瑜莉,王海霞,俞腾飞. 他莫昔芬临床应用研究进展[J]. 国际药学研究杂志,2016,43(2):275-279.
[9]	Johnston S R, Gumbrell L A, Evans T R, et al. A cancer research (UK) randomized phase Ⅱ study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen[J]. Cancer Chemother Pharmacol, 2004, 53(4):341-348.
[10]	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869):805-816.
[11]	冯长根,邓霞飞,向华,等. 治疗乳腺癌的抗雌激素药物研究进展[J]. 中国新药杂志,2006,15(13):1051-1057.
[12]	石磊,许培权. 绝经前激素受体阳性乳腺癌内分泌治疗现状[J]. 实用肿瘤学杂志,2017,31(2):170-174.
[13]	Clark N C, Friel A M, Pru C A, et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors[J]. Cancer Biol Ther, 2016, 17(3):262-271.
[14]	Neubauer H, Yang Y, Sceger H, et al. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells[J]. Menopause, 2011, 18(8):845-850.
[15]	Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric, 2012, 15(5):467-472.
[16]	Neubauer H, Ruan X, Schneck H, et al. Overexpression of progesterone receptor membrane component 1:possible mechanism for increased breast cancer risk with norethisterone in hormone therapy[J]. Menopause, 2013, 20(5):504-510.
[17]	张颖,阮祥燕,田玄玄,等. 孕激素受体膜组分1(PGRMC1)在乳腺癌发生风险方面的研究进展[J]. 首都医科大学学报,2013,34(4):496-500.
[18]	赵越,阮祥燕,张泉东,等. 乳腺癌患者血液中PGRMC1浓度与临床相关性[J]. 首都医科大学学报,2018,39(4):486-493.
[19]	Peluso J J, Gawkowska A, Liu X, et al. Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice[J]. Endocrinology, 2013, 150(11):4846-4854.
[20]	Fasching P A, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receivingneoadjuvant treatment[J]. BMC cancer, 2011, 11:486.
[21]	Elston C W, Ellis I O. Pathological prognostic factors in breast cancer. I. the value of histologicalgrade in breast cancer:experience from a large study with long-term follow-Up[J]. Histopathology, 2002, 41(3A):154-161.
[22]	Aman N A, Doukoure B, Koffi K D, et al. Immunohistochemical evaluation of Ki-67 and comparison with clinicopathologic factors in breast carcinomas[J]. Asian Pac J Cancer Prev, 2019, 20(1):73-79.
[23]	王志新,肖明明. 绝经后乳腺癌妇女服用他莫昔芬后Ki-67及PTEN在子宫内膜中的表达[J]. 中外健康文摘,2011,8(19):18-19.